Company: OSRH
Filing Date: 2025-05-28
Form Type: S-1
Source: 0001213900-25-048346
Chunk: 153

Company: OSR Holdings, Inc.
Filing Date: 2025-05-28
Form: S-1
Chunk 153
---
 any other provisions inconsistent therewith, will (unless otherwise required by law) be prospective only, except to the extent such amendment or change in law permits us to provide broader indemnification rights on a retroactive basis, and will not in any way diminish or adversely affect any right or protection existing thereunder with respect to any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision. Item 15. Recent Sales of Unregistered Securities. Simultaneously with the closing of our IPO, our sponsor, Bellevue Global Life Sciences Investors, LLC (“ Sponsor”), purchased an aggregate of 430,000 units at a price of $10.00 per unit, for an aggregate purchase price of $4,300,000 pursuant to an exemption from registration contained in Section 4(a)(2) of the Securities Act (“ Private Placement Units”). In connection with our IPO, the underwriters were granted a 45-day option from the date of our prospectus issued in connection with our IPO (the “ Over-Allotment Option”) to purchase up to 900,000 additional units to cover over-allotments (the “ Over-Allotment Units”), if any. On February 21, 2023, the underwriters purchased 900,000 Over-Allotment Units fully exercising the Over-Allotment Option. The Over-Allotment Units were sold at an offering price of $10.00 per Over-Allotment Unit, generating additional gross proceeds of $9,000,000 to the Company. II-4 On October 16, 2024, the Company issued an unsecured promissory note to Duksung Co., LTD. (“ Duksung”) in the principal amount of $800,000 (the “ Duksung Promissory Note”). In the event of, and simultaneously with the closing of a Qualified PIPE Financing (as defined in the Duksung Promissory Note), the Duksung Promissory Note automatically converts into Company common stock. On February 25, 2025 we entered into an equity purchase agreement with White Lion GBM Innovation Fund providing that the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to the lesser of (i) $78,900,000 in aggregate gross purchase price of newly issued shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and (ii) the Exchange Cap,